Loading...
Loading...
PSTX| Name | Value |
|---|---|
| Revenues | 71.7M |
| Cost of Revenue | 0.0M |
| Gross Profit | 71.7M |
| Operating Expense | 52.0M |
| Operating I/L | 19.7M |
| Other Income/Expense | 0.5M |
| Interest Income | 0.0M |
| Pretax | 20.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 20.2M |
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing innovative therapeutics to address high unmet medical needs. The company's primary focus is on advancing its CAR-T product candidates, including P-PSMA-101 for metastatic castrate resistant prostate cancer, P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, and P-MUC1C-ALLO1 for various solid tumors. Additionally, Poseida Therapeutics is developing liver-directed gene therapies such as P-OTC-101 and P-FVIII-101, along with other allogeneic dual CAR candidates. The company also has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited, further enhancing its position in the biopharmaceutical industry.
